GLP-1s Beyond Weight Loss and Diabetes: Exploring New Therapeutic Frontiers

/in /tarafından

The potential health benefits of GLP-1 (glucagon-like peptide-1) drugs, known for their use in weight loss and diabetes management, are expanding. Novo Nordisk recently revealed that its GLP-1 drug liraglutide may slow Alzheimer’s disease progression by protecting the brain, according to new mid-stage trial data. Additionally, another study indicated that semaglutide, found in Novo Nordisk’s Wegovy and Ozempic, could aid smoking cessation. These GLP-1 treatments mimic gut hormones to suppress appetite and regulate blood sugar, and researchers believe they might also reduce inflammation and treat other conditions.

However, more extensive research and longer trials are necessary before regulators can approve these drugs for additional uses. The FDA took a significant step in March by approving Wegovy to reduce the risk of serious heart complications. This could increase pressure on insurers to cover these treatments, which often cost around $1,000 per month. Here are other conditions GLP-1s are being tested for:

1. Cardiovascular Health:
• Wegovy has been shown to reduce the risk of heart attack, stroke, and death from cardiovascular causes by 20% in obese patients with heart disease.
• It also alleviated cardiovascular symptoms in patients with obesity, diabetes, and heart failure.
• Eli Lilly’s tirzepatide (in Zepbound and Mounjaro) is being tested in a late-stage trial for obesity and heart failure, expected to conclude this month.

2. Chronic Kidney Disease:
• Novo Nordisk’s Ozempic slowed chronic kidney disease progression in diabetes patients, reducing the risk of death and major cardiac events by 24%.
• Eli Lilly is also studying tirzepatide for obesity and chronic kidney disease in a trial ending in 2026.

3. Fatty Liver Disease:
• Eli Lilly’s Zepbound significantly improved fatty liver disease outcomes in a mid-stage trial.
• Novo Nordisk and other companies like Zealand Pharma, Viking Therapeutics, and Altimmune are also studying GLP-1 treatments for fatty liver disease.

4. Sleep Apnea:
• Zepbound has shown promise in resolving moderate to severe obstructive sleep apnea, and the FDA is reviewing it for this use.

5. Alzheimer’s Disease:
• Novo Nordisk is investigating semaglutide in late-stage trials for Alzheimer’s disease.

6. Addiction:
• Studies are exploring GLP-1s’ potential to curb addictive behaviors, including nicotine and alcohol use. Novo Nordisk is planning a study to see if semaglutide can reduce alcohol consumption.

The broadening scope of GLP-1 applications underscores their potential as versatile treatments for various conditions beyond weight loss and diabetes.

23andMe CEO Anne Wojcicki Proposes to Take Company Private as Stock Plummets

/in /tarafından

Anne Wojcicki, CEO of 23andMe, has submitted a proposal to take the genetic testing company private, as its stock price remains below $1. In a filing with the U.S. Securities and Exchange Commission on Wednesday, Wojcicki offered to buy all outstanding shares of 23andMe’s common stock for 40 cents per share in cash. This proposed price represents an 11% premium to the company’s closing stock price in April.

Wojcicki, who co-founded 23andMe in 2006, initially expressed interest in acquiring the company in April, stating that she would not support any alternative transaction. She aims to complete the transaction “as promptly as possible,” according to the filing. On Wednesday, shares of 23andMe closed at 40 cents.

23andMe, known for its at-home DNA testing kits that provide customers with insights into their ancestry and genetic profiles, went public in 2021 through a merger with a special purpose acquisition company (SPAC), valuing it at approximately $3.5 billion. However, the company has struggled to maintain steady revenue, as customers only need to use its DNA testing product once. Since its public debut, the stock has declined by over 95%.

Wojcicki believes that taking 23andMe private will better equip the company to focus on its long-term mission without the short-term pressures of the public markets. In November, the company received a deficiency letter from the Nasdaq Listing Qualifications Department, giving it 180 days to bring its share price back above $1. In response, 23andMe’s board formed a “Special Committee” in late March to explore options to improve the stock price.

The Special Committee will need to approve or reject Wojcicki’s proposal to take the company private.

Moderna Stock Plummets 20% After Lowering Guidance on EU Sales and U.S. Vaccine Market Challenges

/in /tarafından

Moderna experienced a significant 20% drop in its stock price on Thursday after reporting second-quarter results that, while beating revenue expectations, prompted the company to sharply reduce its full-year sales forecast. The biotech firm now anticipates 2024 product revenue between $3 billion and $3.5 billion, down from its previous estimate of $4 billion.

The revised guidance is attributed to lower-than-expected sales in Europe, heightened competition in the U.S. vaccine market, and potential delays in international revenue. Moderna’s newly approved respiratory syncytial virus (RSV) vaccine, mRESVIA, began shipping in the U.S., but faces stiff competition from existing RSV vaccines by Pfizer and GSK.

Moderna CEO Stephane Bancel highlighted the increased competition for both RSV and Covid vaccines and noted difficulties in securing new contracts with European governments due to tight budgets and existing agreements with Pfizer and BioNTech. The ongoing conflict in Ukraine is also putting strain on government finances.

Despite the current challenges, Bancel expressed optimism for a recovery, projecting sales growth in 2025 and a break-even point by 2026, driven by new product launches.

For the second quarter, Moderna reported:

  • Loss per share: $3.33, better than the expected loss of $3.39
  • Revenue: $241 million, exceeding the $132 million forecast

Revenue from Moderna’s Covid vaccine fell 37% year-over-year, contributing to the company’s net loss of $1.28 billion. However, Moderna achieved a reduction in costs, including a significant drop in sales expenses and a 19% decrease in selling, general, and administrative costs. R&D expenses rose by 6% to $1.2 billion due to increased personnel costs.

Despite these setbacks, Moderna’s stock has risen nearly 20% this year, reflecting confidence in its pipeline and messenger RNA technology. The company is advancing 45 products in development, including a combination vaccine for Covid and flu, and a personalized cancer vaccine with Merck.